Wegovy Tablets Vs Injections

If you have been searching for a clinically proven weight loss treatment and keep hearing about Wegovy tablets, you are not alone — this medication has transformed how obesity is managed in the UK, and millions of people are asking the same questions you are right now. Whether you are frustrated by years of failed diets, struggling with weight-related health conditions, or simply trying to understand whether this treatment is right for you, this guide covers everything you need to know clearly, honestly, and without the medical jargon.

Quick Summary

Wegovy is a prescription-only semaglutide injection used for weight management in adults with obesity or overweight with weight-related health conditions. It works by mimicking a natural gut hormone that reduces appetite, slows digestion, and helps you feel full for longer.

• Wegovy contains semaglutide 2.4mg and is administered as a weekly subcutaneous injection
• It is approved in the UK by the MHRA for adults with a BMI of 30 or above, or 27 with a weight-related condition
• Clinical trials showed average weight loss of around 15% of body weight over 68 weeks
• It must be prescribed by a qualified clinician and used alongside a reduced-calorie diet and exercise
• Common side effects include nausea, vomiting, and constipation, which usually improve over time

Table of Contents

• What Are Wegovy Tablets and How Do They Work?
• Who Is Eligible to Use Wegovy for Weight Loss in the UK?
• Wegovy Dosing Schedule: From Starting Dose to Maintenance
• Common and Serious Side Effects You Should Know About
• How Wegovy Compares to Other Weight Loss Treatments
• How to Get Wegovy Safely in the UK in 2026
• Key Takeaways
• When to Seek Professional Advice
• Scientific References
• FAQs

What Are Wegovy Tablets and How Do They Work?

Despite the common term "Wegovy tablets" being used in everyday conversation, it is worth clarifying that Wegovy is actually administered as a weekly subcutaneous injection rather than an oral tablet. The active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics one of the body's own appetite-regulating hormones. When people search for Wegovy tablets, they are typically looking for information about this injectable semaglutide medication approved specifically for weight management — and that is exactly what we will explore throughout this guide.

GLP-1 is a hormone naturally released by the gut after eating. It signals to the brain that you are full, slows down how quickly food leaves the stomach, and reduces the urge to eat between meals. In people living with obesity, this satiety signalling is often blunted — meaning the brain receives a weaker "I'm full" message, making it far harder to maintain a calorie deficit through willpower alone. Semaglutide works by continuously stimulating GLP-1 receptors at a much higher potency than your body's natural hormone, restoring that sense of fullness and reducing cravings significantly.

The result is not just a modest reduction in appetite — clinical evidence from the landmark STEP trials demonstrated that patients using semaglutide 2.4mg lost an average of around 15% of their body weight compared to around 2.4% in the placebo group. For someone weighing 100kg, that represents a loss of 15kg — a clinically meaningful change that improves blood pressure, blood sugar, joint health, and cardiovascular risk factors simultaneously.

• Semaglutide activates GLP-1 receptors in the brain's appetite control centre (hypothalamus)
• It slows gastric emptying, helping you feel fuller for longer after smaller meals
• It reduces food cravings and the rewarding sensation of eating high-calorie foods
• The 2.4mg weekly dose used in Wegovy is higher than the 1mg used in Ozempic (diabetes)
• It is delivered via a pre-filled pen injection into the abdomen, thigh, or upper arm

Who Is Eligible to Use Wegovy for Weight Loss in the UK?

Not everyone who wants to lose weight will be eligible for Wegovy, and that is an important distinction to understand. In the UK, Wegovy is a prescription-only medicine, meaning it must be assessed and authorised by a qualified prescriber before you can begin treatment. The MHRA-approved criteria for Wegovy use are based on body mass index (BMI) and the presence of weight-related health conditions, following NICE guidance that was updated in 2024.

To be considered eligible, you generally need to have a BMI of 30 kg/m² or above, or a BMI of at least 27 kg/m² alongside at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnoea, or cardiovascular disease. Wegovy is indicated for adults aged 18 and over, and treatment should always be used as part of a reduced-calorie diet and increased physical activity programme — not as a standalone solution.

There are also contraindications to be aware of. Wegovy is not suitable for people with a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN2), or those who have previously experienced a serious allergic reaction to semaglutide. It is also not recommended during pregnancy or breastfeeding. If you are taking medication for type 2 diabetes, your prescriber will need to review your doses carefully, as Wegovy can affect blood sugar levels and interact with insulin or sulphonylureas.

• BMI of 30 or above — eligible without additional conditions
• BMI of 27–29.9 with at least one weight-related comorbidity — also eligible
• Not suitable for use in pregnancy, breastfeeding, or with certain thyroid cancers
• Requires a full medical assessment before prescribing, including medication review
• Ongoing clinical monitoring is recommended throughout treatment

If you are exploring whether Mounjaro weight loss injections (tirzepatide) might be an alternative if you do not meet Wegovy criteria, a prescriber can help compare options based on your individual health profile.

Wegovy Dosing Schedule: From Starting Dose to Maintenance

One of the most common frustrations people encounter with Wegovy is not understanding the dosing schedule — and why it takes several months before you reach the full therapeutic dose. The gradual titration approach is intentional and medically important, as it allows your body to adjust to the medication and significantly reduces the severity of gastrointestinal side effects like nausea and vomiting.

The standard Wegovy dosing schedule begins at 0.25mg once weekly for the first four weeks. This is considered a starting dose and is not sufficient on its own to produce meaningful weight loss — its purpose is purely tolerability. After four weeks, the dose increases to 0.5mg weekly, then to 1mg, followed by 1.7mg, before finally reaching the full maintenance dose of 2.4mg weekly. Each step lasts four weeks, meaning it takes approximately 16 to 20 weeks (four to five months) to reach the target dose.

If you experience intolerable side effects at any stage, your prescriber may recommend staying on the current dose for an additional four weeks before escalating further. Missing doses or stopping treatment early is one of the most common reasons people do not see the results they hoped for, so consistency and patience are crucial. Once at the maintenance dose, many people notice a significant reduction in hunger, fewer cravings, and a natural tendency to eat smaller portions without feeling deprived.

• Week 1–4: 0.25mg once weekly (tolerability phase)
• Week 5–8: 0.5mg once weekly
• Week 9–12: 1mg once weekly
• Week 13–16: 1.7mg once weekly
• Week 17 onwards: 2.4mg once weekly (maintenance)

Dose Phase	Weekly Dose	Duration	Primary Purpose
Phase 1 – Initiation	0.25mg	4 weeks	Tolerability and adjustment
Phase 2 – Escalation	0.5mg	4 weeks	Early appetite suppression
Phase 3 – Escalation	1mg	4 weeks	Increasing therapeutic effect
Phase 4 – Escalation	1.7mg	4 weeks	Near-therapeutic dose
Phase 5 – Maintenance	2.4mg	Ongoing	Full weight loss effect

Common and Serious Side Effects You Should Know About

Being well-informed about side effects before starting any prescription medication is not just sensible — it is essential for managing your expectations and staying safe throughout treatment. Wegovy tablets, as people commonly refer to them, carry a recognised side effect profile that is largely gastrointestinal in nature, particularly during the dose escalation phase. The good news is that most of these effects are temporary and reduce significantly once your body has adapted to the medication.

The most commonly reported side effects include nausea, vomiting, diarrhoea, constipation, abdominal pain, and burping. These typically peak during the first few weeks after each dose increase and tend to settle within a few days. Eating smaller meals, avoiding fatty or spicy foods, and staying well-hydrated can all help manage these symptoms. If nausea is particularly bothersome, taking your injection in the evening may mean you sleep through the worst of it.

More serious but less common side effects include pancreatitis (inflammation of the pancreas), gallstones, and changes in heart rate. There is also a theoretical risk of thyroid tumours based on animal studies, which is why a family history of medullary thyroid carcinoma is a contraindication. In 2026, post-marketing surveillance data continues to support the overall safety of semaglutide when used as directed, and serious adverse events remain rare.

• Nausea and vomiting — most common, especially during dose escalation
• Diarrhoea or constipation — manage with diet and hydration; consider XLS Medical Weight Loss Plus for additional support if needed
• Decreased appetite — expected and part of how the medication works
• Fatigue, headache, and dizziness — usually mild and resolve quickly
• Injection site reactions — redness, itching, or bruising at the injection site
• Seek immediate help if you experience severe abdominal pain, persistent vomiting, or signs of allergic reaction

How Wegovy Compares to Other Weight Loss Treatments

With multiple weight loss treatments now available in the UK — from Orlos (orlistat) 60mg weight loss aid to newer GLP-1 medications — it can feel overwhelming trying to understand which approach is best suited to your situation. The comparison between Wegovy and other treatments comes down to several factors: mechanism of action, efficacy, side effect profile, route of administration, and overall suitability.

Orlistat works by blocking the absorption of dietary fat in the gut, typically producing weight loss of around 5–7% of body weight. It requires a low-fat diet to avoid unpleasant side effects such as oily stools and urgency. While effective for some people, it does not address hunger or cravings — which are often the root cause of difficulty maintaining a calorie deficit. Wegovy, by contrast, directly targets appetite regulation in the brain, producing substantially greater weight loss and with fewer dietary restrictions (beyond the general recommendation to eat healthily).

Mounjaro (tirzepatide) is a newer GLP-1 and GIP dual receptor agonist that has shown even greater weight loss in clinical trials — averaging over 20% body weight reduction in the SURMOUNT-1 trial. Both Wegovy and Mounjaro require a prescription, are administered by injection, and follow similar eligibility criteria. Your prescriber will consider your individual health profile, preferences, and any previous treatments when recommending the most appropriate option for you.

• Wegovy (semaglutide 2.4mg): average 15% body weight loss over 68 weeks
• Mounjaro (tirzepatide): average 20%+ body weight loss in trials
• Orlistat: average 5–7% weight loss; targets fat absorption not appetite
• Wegovy is better tolerated than orlistat for most people in terms of quality of life
• All prescription weight loss treatments require clinical assessment and monitoring

How to Get Wegovy Safely in the UK in 2026

In 2026, accessing Wegovy in the UK has become considerably more straightforward than it was when the medication first launched. It is available through NHS specialist weight management services in some areas, and also through private prescribers and regulated online pharmacies. Regardless of where you obtain it, the prescription process must involve a genuine medical consultation — any provider offering Wegovy without a proper assessment is operating outside of UK regulations and puts your safety at risk.

The safest and most convenient route for many people is through a regulated UK online pharmacy that employs GPhC-registered prescribing pharmacists or GMC-registered doctors. At Cured Pharmacy, for example, you complete a short online health assessment that is reviewed by a qualified prescriber before any prescription is issued. This ensures the medication is appropriate for you, interactions are checked, and you receive proper guidance on how to use your injection pen correctly.

Once prescribed, Wegovy is delivered discreetly to your home in a temperature-controlled package, as the injection pens must be stored in a refrigerator between 2–8°C. You will typically receive ongoing follow-up and the ability to message your prescriber if you experience any problems or have questions about your treatment. Avoid purchasing Wegovy from unregulated websites, social media vendors, or any source that does not require a prescription — counterfeit or improperly stored semaglutide poses serious health risks.

• Always obtain Wegovy through a GPhC-registered pharmacy or GMC-registered doctor
• Complete a full health assessment before treatment begins — this is a legal and safety requirement
• Store injection pens in the fridge at 2–8°C; do not freeze them
• Follow the injection technique guidance provided with your pen or by your pharmacist
• Attend follow-up reviews and report any concerning symptoms promptly
• Avoid buying from unregulated online sources — counterfeit products are a growing risk

If you are also managing other conditions alongside your weight, such as thyroid issues, consider a Newfoundland thyroid test to ensure your thyroid function is optimised before starting weight loss treatment. Similarly, if digestive discomfort becomes a concern during your Wegovy journey, products like XLS Medical Direct Fat Binder sachets may offer complementary dietary support.

Key Takeaways

• Wegovy tablets is the widely used term for the semaglutide 2.4mg weekly injection, a clinically proven GLP-1 weight loss treatment approved in the UK
• It works by mimicking the GLP-1 gut hormone to suppress appetite, slow digestion, and significantly reduce caloric intake
• The dosing schedule takes approximately four to five months to reach the full 2.4mg maintenance dose — patience and adherence are key
• Side effects are predominantly gastrointestinal and temporary, with serious events being rare when used under proper medical supervision
• Always obtain Wegovy through a regulated UK prescriber or pharmacy, and never purchase from unverified online sources

When to Seek Professional Advice

There are specific situations where you should contact your prescriber or seek urgent medical attention while using Wegovy. If you experience severe or persistent abdominal pain — particularly pain that radiates to your back — this could be a sign of pancreatitis and requires immediate medical evaluation. Similarly, symptoms of a serious allergic reaction such as facial swelling, difficulty breathing, or a widespread rash should prompt emergency care without delay.

Contact your prescriber as soon as possible if you notice:

• Severe nausea or vomiting that prevents you from eating or drinking for more than 24 hours
• Signs of low blood sugar (if you also take diabetes medication): shakiness, sweating, confusion
• A rapid or irregular heartbeat that is new or unexplained
• Changes in vision, especially if you have pre-existing diabetic retinopathy
• A lump or swelling in the neck area, hoarseness, or difficulty swallowing (possible thyroid symptoms)
• Significant mood changes or thoughts of self-harm — though rare, these have been reported with semaglutide-class drugs

Routine check-ins with your prescriber are equally important. Even when things are going smoothly, regular reviews allow dose adjustments, weight progress monitoring, and early identification of any emerging issues. Do not stop treatment abruptly without medical advice, as weight regain is common after discontinuation and your prescriber can help you plan an appropriate stopping or maintenance strategy.

Frequently Asked Questions

How long does it take to see results with Wegovy tablets?

Results with Wegovy tablets typically begin within the first four weeks, with noticeable weight loss appearing by weeks eight to twelve. Most clinical trials reported significant reductions in body weight after six months of consistent use at the maintenance dose, combined with a reduced-calorie diet and increased physical activity.

Is Wegovy safe to take long term?

Wegovy is considered safe for long-term use when prescribed and monitored by a qualified healthcare professional. The STEP clinical trials, which ran for up to 68 weeks, demonstrated a strong safety profile. Regular reviews by your prescriber are recommended to monitor for side effects and ensure continued suitability throughout treatment.

Can you take Wegovy with other medications?

Wegovy can interact with certain medications, particularly those used to manage diabetes such as insulin or sulphonylureas, increasing the risk of hypoglycaemia. Always disclose your full medication list to your prescriber before starting treatment. Your pharmacist can also check for interactions and advise on safe co-administration of any medicines you currently take.

What is the correct dose of Wegovy for weight loss?

The correct dose of Wegovy for weight loss follows a gradual escalation schedule, starting at 0.25mg weekly for four weeks, then increasing every four weeks through 0.5mg, 1mg, and 1.7mg, until reaching the maintenance dose of 2.4mg weekly. This slow titration reduces gastrointestinal side effects and helps the body adjust comfortably to the medication.

For additional support during your weight loss journey, Wegovy tablets may be complemented by evidence-based lifestyle tools — including Formoline L112 tablets, which can assist with dietary fat management alongside your main prescription treatment.

Scientific References

1. National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity (TA875). NICE, 2023.
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). The Lancet, 2021.
3. Medicines and Healthcare products Regulatory Agency (MHRA). Wegovy (semaglutide) Product Information. MHRA, UK.